Ketamine Therapy

A rapid-acting approach studied for treatment-resistant depression-what the evidence supports, and what it does not.

Explore ketamine therapy for treatment-resistant depression-how it works, what research shows, safety considerations, and what to expect during treatment.

Three Different Things Called Ketamine Therapy

Ketamine, developed as an anesthetic, produces antidepressant effects in some people within hours rather than the weeks typical of standard antidepressants. That is a genuine and well-replicated finding, but "ketamine therapy" covers three products with very different regulatory standing:

Esketamine nasal spray (SPRAVATO) is FDA-approved for adults and is delivered only in certified healthcare settings under a restricted programme (REMS), with supervised administration and a required monitoring period afterwards.

Racemic ketamine, usually given intravenously, is an approved anesthetic used off-label for depression. Off-label use is legal and common in medicine, but it means depression-specific labeling, standardized protocols and long-term safety data are not established in the same way.

Compounded ketamine products, including at-home oral or nasal formulations, are not FDA-approved, are not evaluated for safety or effectiveness in depression, and have been the subject of FDA warnings about unsupervised use.

What Esketamine Is Approved For

Current SPRAVATO prescribing information distinguishes two uses in adults:

Treatment-resistant depression: esketamine may be used as monotherapy or together with an oral antidepressant.

Depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior: esketamine is used in conjunction with an oral antidepressant.

An important limitation appears in the labeling itself: effectiveness in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Improvement in depressive symptoms is not the same as reduced suicide risk, and esketamine is not a substitute for hospitalization or other clinically indicated safety care. If you are in crisis right now, see our Crisis Resources page for verified urgent support.

How Ketamine May Work

Ketamine acts on the glutamate system rather than the serotonin pathways targeted by most conventional antidepressants. Beyond that, mechanism and clinical effect need to be kept apart: the rapid antidepressant effect is established in trials, while the biological explanation for it is not settled in humans.

How Treatment Is Delivered

Ketamine and esketamine are not self-administered treatments. Esketamine is given in a certified healthcare setting where you are monitored for at least two hours after each dose because of sedation, dissociation and blood-pressure effects; it cannot be dispensed for use at home, and you should not drive until the next day after a restful sleep. Racemic ketamine infusions are given in clinical settings with monitoring, and you remain awake.

Schedules, number of sessions and any continuation of treatment differ by product, setting and individual response, and are set by the treating clinician rather than by a universal protocol. This page deliberately does not list doses or session schedules. Costs also vary widely: esketamine is often covered by insurance for treatment-resistant depression, while off-label infusions are frequently paid out of pocket - ask a specific provider and your insurer for figures.

Whether ketamine is a reasonable option for you depends on your history, other conditions and current medications, and requires evaluation by a qualified psychiatrist. Ketamine is not a first-line treatment.

Safety and What Remains Uncertain

Common effects during and shortly after treatment include dissociation, dizziness, nausea, raised blood pressure and perceptual changes, which usually resolve within a couple of hours under supervision. Cardiovascular conditions, psychosis and substance use history are among the factors clinicians weigh when considering treatment; that assessment is individual and cannot be resolved from a list on a web page.

Longer-term questions remain open, including durability of benefit, effects of repeated use over years, bladder toxicity with frequent or heavy use, and potential for misuse. These are among the reasons supervised delivery matters and unsupervised or compounded at-home use is discouraged.

Across trials, a substantial proportion of people with treatment-resistant depression respond, often quickly, and effects commonly fade without continued care. That is a meaningful result for a group with few good options - and it is a treatment decision to make with a clinician, not a guaranteed outcome.

Frequently asked questions

How quickly does ketamine work for depression?

Improvement is often reported within hours to days, much faster than the weeks typical of standard antidepressants. Response is not universal, and benefit commonly fades without a continued treatment plan, which is why care is delivered and reviewed by a clinician over time.

Is ketamine therapy safe?

In carefully selected patients, in a supervised medical setting, side effects are usually transient and manageable. Risk is higher outside supervised settings, and compounded at-home ketamine products are not FDA-approved or evaluated for depression. Long-term data are still accumulating.

Can ketamine prevent suicide?

No treatment should be presented that way. Esketamine is approved to treat depressive symptoms in adults with MDD who have acute suicidal ideation or behavior, used with an oral antidepressant, but its labeling states that effectiveness in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. If you are in immediate danger, use the crisis resources on our Crisis Resources page or local emergency services.

Does ketamine therapy cause hallucinations?

Ketamine can cause dissociation - feeling detached from your body or surroundings - and perceptual changes, which are not the same as hallucinations and typically resolve within a couple of hours. Whether these experiences contribute to the antidepressant effect is still debated in the research.

Related on Beiing

Sources

  1. SPRAVATO (esketamine) nasal spray - Prescribing Information - Janssen Pharmaceuticals via DailyMed (U.S. National Library of Medicine)
  2. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders (October 2023) - U.S. Food and Drug Administration
  3. SPRAVATO approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression (21 January 2025) - Johnson & Johnson (manufacturer press release)
  4. Ketamine comparable to ECT for many patients with refractory depression (ELEKT-D trial, 2023) - Psychiatric News (American Psychiatric Association)

Written by Beiing Editorial Team · Editorially reviewed by Beiing Editorial & Research Review · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.

Pages in this section

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.